We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Metabolic and neuropsychic status in chronic brain ischemia: Correction of disorders.
- Authors
Konoplya, A. I.; Bystrova, N. A.; Shulginova, A. A.; Sunyaikina, O. A.; Dolgareva, S. A.; Khorlyakova, O. V.
- Abstract
Introduction: Chronic brain ischemia (CBI) is one the causes of disability and Russian population mortality, moreover inflicting a great economic loss to the society. The development of a strategy for pharmacological correction of this pathology is one of the urgent, timely tasks. The aim of the study is to determine the clinical and laboratory efficacy of glutoxim among patients with CBI of I and II stages. Materials and Methods: A total of 48 patients at the age of 50 ± 5 years from the Neurological Department of the BME "Kursk Regional Clinical Hospital" were under constant observation with a verified diagnosis of CBI in presence with II stage hypertensive disease, thus 24 patients with CBI of the I stage and the II stage, respectively, received basic pharmacological therapy (enalapril, vinpocetine, ceraxon, and mexicor). Half of the patients with each stage of the disease received an additional preparation with immunomodulatory effect glutoxim. Metabolic and immunological disorders were assessed by total antioxidant activity, acylhydroperoxides, malondialdehyde, stable metabolites of nitric oxide concentrations in plasma and erythrocytes, catalase activity, superoxide dismutase, plasma levels of C-reactive protein, endothelin-1, erythropoietin, neopterin, and immunologically - according to the concentrations of cytokines tumor necrosis factor-alpha, interleukin 1ß, interleukin 17, and interferon-gamma in blood plasma. The complex of patients' examination included, in addition to general clinical status, the assessment of neuropsychic one. Results and Discussion: In the case of CBI, to a greater extent on II stage, in the presence of the hypertensive disease, similar metabolic disorders were revealed, indicating the activation of lipid peroxidation, the development of oxidative stress and endothelial dysfunction. The inclusion of glutoxim in complex pharmacotherapy contributes, especially at an early stage of CBI, to a reduction in the severity of subjective disorders, indicators of neurological status, cognitive dysfunction, and laboratory metabolic parameters. Conclusion: The obtained data indicate the effectiveness of glutoxim in the basic pharmacological treatment of CBI.
- Publication
Drug Invention Today, 2019, Vol 12, Issue 11, p2741
- ISSN
0975-7619
- Publication type
Article